JP5784868B2 - 分子撮像用の超音波造影剤及び粒子の使用 - Google Patents
分子撮像用の超音波造影剤及び粒子の使用 Download PDFInfo
- Publication number
- JP5784868B2 JP5784868B2 JP2007542405A JP2007542405A JP5784868B2 JP 5784868 B2 JP5784868 B2 JP 5784868B2 JP 2007542405 A JP2007542405 A JP 2007542405A JP 2007542405 A JP2007542405 A JP 2007542405A JP 5784868 B2 JP5784868 B2 JP 5784868B2
- Authority
- JP
- Japan
- Prior art keywords
- contrast agent
- metal
- substrate
- particles
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/225—Microparticles, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6941—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a granulate or an agglomerate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Acoustics & Sound (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicinal Preparation (AREA)
Description
− 例として、30分以上の間に標的とされた器官における検出を可能にする、血液における安定な且つ十分な寿命;
− 毛細血管を通過することを可能とするための8ミクロン未満の粒子の大きさ;
− 非毒性のもの、又は、許容可能な毒性;
− 十分な反射の向上;
− 生産及び臨床的な使用の容易さ;
− 高度に特異的な標的とすることを可能にすること、
のうち可能な限り多数のものを有するべきである。
− その基材に存する、金属のナノ粒子。これらを、その基材へ共有又は非共有結合させることができるか、その基材の構成要素によって囲むことができるか、又は、その基材における孔内に存する(図7a)。
これらの安定化された小滴を、例えば標的とされる場合に、超音波造影剤として、それ自体によって使用することができる。その小滴のシェルの中に、上に、又は下に、金属のナノ粒子を加えることによって、反射の向上における増加を、得ることができる。この実施形態において、本発明に従った基材は、その小滴の分散物である。本発明の小滴は、ナノメートルの又は結局マイクロメートルの寸法を有すると共に、体の組織との低い音響の不整合を有する。これは、より大きい寸法(マイクロメートル)及び人間の組織との高い音響の不整合を通常有する先行技術のマイクロバブルと対照的なものである。また、本発明の小滴は、先行技術のマイクロバブルと比較されると、増加させられた寿命を有する。
‘r(k)’は、非圧縮性の材料の振幅の反射係数である、
‘t’は、媒質1(例.水)、媒質2(超音波造影層/剤)、及び、媒質3(例.基体)の間における複素数の透過係数である、
‘r’は、媒質1(例.水)、媒質2(超音波造影層/剤)、及び、媒質3(例.基体)の間における複素数の反射係数である(図1を参照のこと)、
‘12’は、媒質1(例.水)及び2(例.金の層)の間の界面及び1から2へ進行する音の方向を指し示す。
‘k’は、造影層における超音波の波数である。
‘d’は、造影層の厚さである。
及び、
その向上は、
[式2]
ここで、‘r(k)’は、非圧縮性の材料の振幅の反射係数であると共に、r0は、造影剤無しの基体の表面の振幅の反射係数である。
本例は、小さい金属のナノ粒子のクラスター化が、70nmより上の直径を備えた金属の粒子について許容可能な代替物を提供することを例示する。
Claims (11)
- 複数の金属のナノ粒子を含む医学の診断及び撮像のための超音波造影剤において、
上記の複数の金属のナノ粒子は、非タンパク質性の生体適合性又は生分解性の基材粒子にカプセル化され、及び/又は、非タンパク質性の生体適合性又は生分解性の基材粒子に付加され、
上記基材粒子の基材は、炭水化物、脂質、合成のポリマー、界面活性剤、及びエマルジョン、又はそれらの混合物からなる群より選択され、
上記の金属のナノ粒子は、1ないし100nmの間の直径を有し、
上記の金属のナノ粒子は、上記の基材において少なくとも2%体積/体積の濃度で存在し、上記の金属のナノ粒子の表面に1つ以上の標的とする分子が付加され、超音波の反射を向上させるための超音波造影剤。 - 請求項1に記載の超音波造影剤において、
上記の基材は、小胞のシェルである、超音波造影剤。 - 請求項1又は2に記載の超音波造影剤において、
上記の金属のナノ粒子は、少なくとも35×105g/cm2sの音響インピーダンスを有する、超音波造影剤。 - 請求項1から3までのいずれか1項に記載の超音波造影剤において、
上記の金属のナノ粒子は、50×105g/cm2sより高い音響のインピーダンスを有する、超音波造影剤。 - 請求項1から4までのいずれか1項に記載の超音波造影剤において、
上記の金属のナノ粒子は、1ないし50nmの間の直径を有する、超音波造影剤。 - 請求項1から5までのいずれか1項に記載の超音波造影剤において、
上記の金属は、非磁性の金属である、超音波造影剤。 - 請求項6に記載の超音波造影剤において、
上記の非磁性の金属は、金、銀、白金、パラジウム、タングステン、タンタル若しくはレニウム又はそれらの混合物からなる群より選択される、超音波造影剤。 - 請求項1から7までのいずか1項に記載の超音波造影剤において、
上記の金属は、貴金属である、超音波造影剤。 - 請求項1から8までのいずか1項に記載の超音波造影剤において、
上記の基材粒子は、1ないし8マイクロメートルの間の直径を有する、超音波造影剤。 - 請求項1から8までのいずか1項に記載の超音波造影剤において、
上記の基材粒子は、25ないし250ナノメートルの間の直径を有する、超音波造影剤。 - 超音波の反射を向上させる超音波造影剤の製造のための、複数の金属のナノ粒子を含む非タンパク質性の基材の粒子の使用において、
上記の金属のナノ粒子は、1ないし100nmの間の直径を有し、
上記の金属のナノ粒子は、上記の基材において少なくとも2%体積/体積の濃度で存在し、上記の金属のナノ粒子の表面に1つ以上の標的とする分子が付加され、
上記の基材は、炭水化物、脂質、合成のポリマー、エマルジョン又はそれらの混合物からなる群より選択される、使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04105948 | 2004-11-19 | ||
| EP04105948.6 | 2004-11-19 | ||
| PCT/IB2005/053763 WO2006054240A2 (en) | 2004-11-19 | 2005-11-15 | Ultrasound contrast agents for molecular imaging |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013103476A Division JP5809661B2 (ja) | 2004-11-19 | 2013-05-15 | 分子撮像用の超音波造影剤及び粒子の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008520648A JP2008520648A (ja) | 2008-06-19 |
| JP5784868B2 true JP5784868B2 (ja) | 2015-09-24 |
Family
ID=36407523
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007542405A Expired - Fee Related JP5784868B2 (ja) | 2004-11-19 | 2005-11-15 | 分子撮像用の超音波造影剤及び粒子の使用 |
| JP2013103476A Expired - Fee Related JP5809661B2 (ja) | 2004-11-19 | 2013-05-15 | 分子撮像用の超音波造影剤及び粒子の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013103476A Expired - Fee Related JP5809661B2 (ja) | 2004-11-19 | 2013-05-15 | 分子撮像用の超音波造影剤及び粒子の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090148385A1 (ja) |
| EP (1) | EP1824521B1 (ja) |
| JP (2) | JP5784868B2 (ja) |
| CN (2) | CN103480007B (ja) |
| WO (1) | WO2006054240A2 (ja) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7925329B2 (en) * | 2004-10-08 | 2011-04-12 | Proteus Biomedical, Inc. | Implantable doppler tomography system |
| EP1799113A4 (en) * | 2004-10-08 | 2010-07-07 | Proteus Biomedical Inc | CONTINUOUS FIELD TOMOGRAPHY |
| US20080058656A1 (en) * | 2004-10-08 | 2008-03-06 | Costello Benedict J | Electric tomography |
| EP1824521B1 (en) | 2004-11-19 | 2015-01-07 | Koninklijke Philips N.V. | Ultrasound contrast agents for molecular imaging |
| US20110066057A1 (en) * | 2005-10-31 | 2011-03-17 | Zdeblick Mark J | Electrical Angle Gauge |
| US9149545B2 (en) | 2005-11-02 | 2015-10-06 | General Electric Company | Nanoparticle-based imaging agents for X-ray/computed tomography and methods for making same |
| US20070167758A1 (en) * | 2005-11-23 | 2007-07-19 | Costello Benedict J | Automated detection of cardiac motion using contrast markers |
| US20070161894A1 (en) * | 2005-12-23 | 2007-07-12 | Mark Zdeblick | Ultrasound synchrony measurement |
| US8003883B2 (en) | 2007-01-11 | 2011-08-23 | General Electric Company | Nanowall solar cells and optoelectronic devices |
| US7977568B2 (en) | 2007-01-11 | 2011-07-12 | General Electric Company | Multilayered film-nanowire composite, bifacial, and tandem solar cells |
| US20080208068A1 (en) * | 2007-02-26 | 2008-08-28 | Timothy Robertson | Dynamic positional information constrained heart model |
| WO2009009746A1 (en) * | 2007-07-11 | 2009-01-15 | Proteus Biomedical, Inc. | Spread spectrum electric tomography |
| US20100280366A1 (en) * | 2008-05-13 | 2010-11-04 | Lawrence Arne | Continuous field tomography systems and methods of using the same |
| WO2009158601A2 (en) * | 2008-06-27 | 2009-12-30 | Proteus Biomedical, Inc. | Clinical applications for electrical tomography derived metrics |
| WO2010065539A2 (en) * | 2008-12-02 | 2010-06-10 | Proteus Biomedical, Inc. | Optimial drive frequency selection in electrical tomography |
| GB0908506D0 (en) * | 2009-05-18 | 2009-06-24 | Imagination Tech Ltd | Method and apparatus for drawing polygons |
| GB201010831D0 (en) * | 2010-06-28 | 2010-08-11 | Ct Angewandte Nanotech Can | A micellular combination comprising a nanoparticle and a plurality of surfmer ligands |
| JP2014196281A (ja) * | 2012-08-01 | 2014-10-16 | 健輔 江頭 | 医薬組成物 |
| WO2017027874A1 (en) * | 2015-08-13 | 2017-02-16 | Northeastern University | Biomaterials for combined radiotherapy and immunotherapy of cancer |
| US10881735B2 (en) * | 2015-11-20 | 2021-01-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Phase change nanodroplet conjugates for targeted delivery |
| JP6130538B1 (ja) * | 2016-03-04 | 2017-05-17 | 伯東株式会社 | 超音波伝達効率向上組成物、超音波診断用ゲル組成物及び超音波撮影方法 |
| WO2018070992A1 (en) * | 2016-10-11 | 2018-04-19 | Avent, Inc. | System and method for echogenically enhancing nerve fibers using targeted metallic particles |
| JPWO2024166416A1 (ja) * | 2023-02-06 | 2024-08-15 | ||
| CN116445761B (zh) * | 2023-03-01 | 2025-02-18 | 湖南大学 | 一种具有磁粒子成像性质的Pd基合金、MPI造影剂、制备方法及其应用 |
| US20250177577A1 (en) * | 2023-11-30 | 2025-06-05 | Translational And Fundamental Technologies Institute Llc | Radiopaque nanoparticles for medical imaging |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT81498B (pt) * | 1984-11-23 | 1987-12-30 | Schering Ag | Processo para a preparacao de composicoes para diagnostico contendo particulas magneticas |
| JPS61207344A (ja) * | 1985-03-11 | 1986-09-13 | Akio Hagiwara | リンパ系造影剤 |
| US4904497A (en) | 1987-03-16 | 1990-02-27 | Olin Corporation | Electromagnetic solder tinning method |
| NZ244147A (en) * | 1991-09-03 | 1994-09-27 | Hoechst Ag | Echogenic particles which comprise a gas and at least one shaping substance, and their use as diagnostic agents |
| US6818199B1 (en) * | 1994-07-29 | 2004-11-16 | James F. Hainfeld | Media and methods for enhanced medical imaging |
| US6214388B1 (en) * | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| JPH10206403A (ja) * | 1997-01-22 | 1998-08-07 | Hitachi Constr Mach Co Ltd | 試料表面処理法および試料表面処理剤 |
| JPH10330288A (ja) * | 1997-06-03 | 1998-12-15 | Mitsubishi Chem Corp | 金属微粒子複合体及びこれを利用した造影剤 |
| US6165440A (en) * | 1997-07-09 | 2000-12-26 | Board Of Regents, The University Of Texas System | Radiation and nanoparticles for enhancement of drug delivery in solid tumors |
| US5945293A (en) * | 1997-10-09 | 1999-08-31 | Coulter International Corp. | Protein-colloidal metal-aminodextran coated particle and methods of preparation and use |
| US7097826B2 (en) * | 1999-12-23 | 2006-08-29 | Health Research, Inc. | Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals |
| DE10037832C2 (de) * | 2000-08-03 | 2003-08-21 | Karlsruhe Forschzent | Kontrastmittel für medizinische Diagnostik und dessen Verwendung |
| US6676963B1 (en) | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
| WO2002100444A1 (en) * | 2001-06-08 | 2002-12-19 | Biosphere Medical Inc. | Colloidal metal labelled microparticles, their production and use |
| US6797257B2 (en) * | 2001-06-26 | 2004-09-28 | The Board Of Trustees Of The University Of Illinois | Paramagnetic polymerized protein microspheres and methods of preparation thereof |
| US7563457B2 (en) | 2001-10-02 | 2009-07-21 | The Regents Of The University Of California | Nanoparticle assembled hollow spheres |
| US7500953B2 (en) * | 2003-01-25 | 2009-03-10 | Seno Medical Instruments, Inc. | High contrast optoacoustic imaging using nanoparticles |
| JP5015606B2 (ja) * | 2004-01-15 | 2012-08-29 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | モレキュラーイメージング用の超音波造影剤 |
| EP1824521B1 (en) * | 2004-11-19 | 2015-01-07 | Koninklijke Philips N.V. | Ultrasound contrast agents for molecular imaging |
-
2005
- 2005-11-15 EP EP05804156.7A patent/EP1824521B1/en not_active Expired - Lifetime
- 2005-11-15 JP JP2007542405A patent/JP5784868B2/ja not_active Expired - Fee Related
- 2005-11-15 CN CN201310341783.5A patent/CN103480007B/zh not_active Expired - Fee Related
- 2005-11-15 US US11/719,310 patent/US20090148385A1/en not_active Abandoned
- 2005-11-15 CN CNA2005800392810A patent/CN101437551A/zh active Pending
- 2005-11-15 WO PCT/IB2005/053763 patent/WO2006054240A2/en not_active Ceased
-
2013
- 2013-05-15 JP JP2013103476A patent/JP5809661B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008520648A (ja) | 2008-06-19 |
| EP1824521B1 (en) | 2015-01-07 |
| CN103480007B (zh) | 2016-02-03 |
| JP2013163688A (ja) | 2013-08-22 |
| JP5809661B2 (ja) | 2015-11-11 |
| CN103480007A (zh) | 2014-01-01 |
| EP1824521A2 (en) | 2007-08-29 |
| US20090148385A1 (en) | 2009-06-11 |
| WO2006054240A2 (en) | 2006-05-26 |
| CN101437551A (zh) | 2009-05-20 |
| WO2006054240A3 (en) | 2009-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5809661B2 (ja) | 分子撮像用の超音波造影剤及び粒子の使用 | |
| Lanza et al. | In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy | |
| JP4082463B2 (ja) | 部位特異的結合システム、影像組成物及び方法 | |
| JP4202139B2 (ja) | 温度依存性造影剤による強化型超音波検出 | |
| Abesekara et al. | Recent advances in surface modification of micro-and nano-scale biomaterials with biological membranes and biomolecules | |
| US20080279783A1 (en) | Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production | |
| Du et al. | Preparation and imaging investigation of dual-targeted C3F8-filled PLGA nanobubbles as a novel ultrasound contrast agent for breast cancer | |
| WO2007027584A9 (en) | Deposit contrast agents and related methods thereof | |
| US20100028261A1 (en) | Molecular Specific Photoacoustic Imaging | |
| JP2001511765A (ja) | 改良された診断/治療用薬剤 | |
| WO1993020802A1 (en) | Acoustically reflective liposomes and methods to make and use the same | |
| EP1416974A1 (en) | Gas microsphere liposome composites | |
| Oddo et al. | Next generation ultrasound platforms for theranostics | |
| JP5015606B2 (ja) | モレキュラーイメージング用の超音波造影剤 | |
| JP2007517858A5 (ja) | ||
| Zhong et al. | VEGFR2 targeted microbubble-based ultrasound molecular imaging improving the diagnostic sensitivity of microinvasive cervical cancer | |
| Gafar et al. | Applications of peptides in nanosystems for diagnosing and managing bacterial sepsis | |
| Hall et al. | Time evolution of enhanced ultrasonic reflection using a fibrin-targeted nanoparticulate contrast agent | |
| CN116942850B (zh) | 一种用于易损斑块的纳米药物递送系统 | |
| KR101675948B1 (ko) | 동맥경화 진단용 키토산 나노입자 복합체, 이의 제조방법 및 이를 포함하는 조영제 조성물 | |
| Kooiman et al. | Surface contact of bound targeted microbubbles | |
| EP3381929A1 (en) | Targeted microbubbles for detection of glycocalyx | |
| JP2008540641A (ja) | 造影剤 | |
| Long et al. | Collagen IV-targeted phase-change nanoparticles illuminate early liver fibrosis staging via ultrasound molecular imaging | |
| CN120361256A (zh) | 一种靶向psma受体的纳米复合体、制备方法及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110719 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111018 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120417 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120711 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120719 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121017 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150428 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150723 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5784868 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |